All Seattle Genetics articles
-
BusinessPfizer to buy cancer biotech Seagen for $43 billion
Antibody-drug conjugate specialist will fill Pfizer’s cancer pipeline
-
BusinessTakeda tightens focus on core areas with multiple deals
Japanese firm is remodelling its R&D efforts through collaboration and licensing deals, and selling off non-core businesses
-
BusinessSeattle Genetics cancels Immunomedics deal
Settlement also resolves disputes with shareholders
-
Business$2bn Immunomedics–Seattle Genetics deal delayed amid shareholder infighting
Major investor venBio seeks to derail deal and replace board members